This HTML5 document contains 157 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n8http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q55309836
rdf:type
wikibase:Item
schema:description
επιστημονικό άρθρο บทความทางวิทยาศาสตร์ научни чланак scientific article 2012年學術文章 articol științific наукова стаття, опублікована в липні 2012 2012年學術文章 мақолаи илмӣ tieteellinen artikkeli wissenschaftlicher Artikel مقالهٔ علمی artikulong pang-agham wetenschappelijk artikel գիտական հոդված ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ article científic 2012年学术文章 2012年學術文章 vědecký článek article scientific vitenskapelig artikkel 2012年の論文 mokslinis straipsnis სამეცნიერო სტატია 2012年学术文章 2012年學術文章 научна статия 2012 nî lūn-bûn научни чланак naučni članak мақолаи илмӣ articolo scientifico tudományos cikk artigo científico (publicado na 2012) 2012年学术文章 سائنسی مضمون artículu científicu article scientifique (publié 2012) videnskabelig artikel (udgivet 2012) artículo científico publicado en 2012 bilimsel makale 2012年学术文章 artykuł naukowy vitskapeleg artikkel artigo científico vetenskaplig artikel מאמר מדעי scienca artikolo مقالة علمية 2012年學術文章 teaduslik artikkel artikull shkencor 2012년 논문 научная статья 2012年學術文章 bài báo khoa học vedecký článok artigo científico (publicado na 2012) 2012年学术文章
p:P577
wds:Q55309836-BE091EB9-ED71-4FE3-B726-CC77555E8B17
wdt:P577
2012-07-02T00:00:00Z
p:P407
wds:Q55309836-D7B241CE-77ED-444A-A6AA-41E4CF34CD5F
wdt:P407
wd:Q1860
p:P2860
wds:Q55309836-0830563F-7769-407D-A425-C79B37D325C4 wds:Q55309836-4121A0BB-E967-4907-940C-DD0455B3E2C6 wds:Q55309836-0F452511-210D-48E0-80BE-6DFE956F6964 wds:Q55309836-21F7883D-D983-47C3-A830-432A456AEE8A wds:Q55309836-6A2A7E90-6C78-404A-9C1F-8324923022B9 wds:Q55309836-78CCB984-5C9C-4D27-87FD-D7771736FC7B wds:Q55309836-4BC32A1D-C9A7-4CF7-99C9-564E72253585 wds:Q55309836-4C2E849E-290E-4192-AF37-506ED037DF54 wds:Q55309836-A0B34257-09C5-4426-BF7D-95065682B27F wds:Q55309836-A46C21CD-042D-43F8-BF3C-75E267325552 wds:Q55309836-A7FA718D-38AA-47AC-9E64-6F758F01B6FC wds:Q55309836-B4C76692-81D4-4EDE-9375-5D2F48B33FD6 wds:Q55309836-791348DB-34FC-4FA0-9510-A363D5C624A6 wds:Q55309836-BD35114D-32A8-4674-9E9E-BBD3436A57B6 wds:Q55309836-EE05E848-A704-4DA5-B5E2-AE2565471FE9 wds:Q55309836-9068C36F-9051-408D-B75A-861C5027AFE3 wds:Q55309836-F8881042-8C7E-4191-A5C6-AEC8B2820F5F wds:Q55309836-DC8E0B2D-E711-4D73-8A5F-D3164D7BA671
wdt:P2860
wd:Q34621670 wd:Q33388853 wd:Q33389302 wd:Q34224801 wd:Q53599393 wd:Q47582438 wd:Q37946342 wd:Q28202824 wd:Q40258791 wd:Q44666449 wd:Q37607076 wd:Q37820097 wd:Q39645683 wd:Q34147803 wd:Q30496972 wd:Q33773306 wd:Q39840659 wd:Q37075231
p:P2093
wds:Q55309836-3F27B527-6BD9-4F4D-99D2-CF9EBD3511C7 wds:Q55309836-D1D16FE3-463C-4145-B304-41206069ABE5 wds:Q55309836-D73086CB-BF3E-428F-99C8-C32D01C9427C wds:Q55309836-F8022939-D807-4B03-A93B-5A545C23E727 wds:Q55309836-09B00A41-3FCB-4C85-9289-51103F260263
wdt:P2093
Stella Kim Rodica Morariu-Zamfir Sandrine Payrard John M Lambert Silvana de Castro Farial
rdfs:label
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
skos:prefLabel
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
schema:name
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
p:P50
wds:Q55309836-84432408-6A38-4613-B1F5-382CC0E9B747 wds:Q55309836-92DDC324-D269-45E8-8A40-366394C4DD05 wds:Q55309836-52217C2B-E701-42D0-9E57-E1484EDCAED1 wds:Q55309836-58DA020E-EFA7-4803-8A02-BD6D57BB9C80 wds:Q55309836-2219F1F7-62ED-497A-A11B-9FC377BA8CCA wds:Q55309836-d3e167b1-401c-50de-f20b-b0e1918cd3e9 wds:Q55309836-BA323DC0-FEF3-4DA8-805F-386B643E394D wds:Q55309836-BC2A33C8-5CFC-4C45-BC30-2ADE3F1147B1 wds:Q55309836-D5343EF8-D8D8-4D2D-898E-10204440C8F5
wdt:P50
wd:Q91632799 wd:Q88022461 wd:Q114726218 wd:Q91522188 wd:Q40235097 wd:Q90287448 wd:Q96200428 wd:Q114726224 wd:Q106561774
p:P1476
wds:Q55309836-471C4457-C762-4E42-8A81-FEC2925F46DD
wdt:P1476
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
p:P304
wds:Q55309836-2A422F47-FABB-48E6-B4FB-CCE716B76FBC
wdt:P304
2776-2782
p:P31
wds:Q55309836-EE39190D-94CE-44C6-A110-F4D2A1733334
wdt:P31
wd:Q13442814
p:P921
wds:Q55309836-0A88E891-4F5A-4B02-A5F3-3F66F2A37477
wdt:P921
wd:Q181600
p:P698
wds:Q55309836-157CB7EB-FB3F-4C6E-9820-62B007372B9F
wdtn:P698
n12:22753910
wdt:P698
22753910
p:P1433
wds:Q55309836-5C860313-4089-48BF-9F2D-837D2EFC6F64
wdt:P1433
wd:Q400292
p:P433
wds:Q55309836-6093C8B0-FEDC-49E2-8A8A-BA6ACE4373FD
p:P478
wds:Q55309836-ED29C501-02C1-40E6-8593-803066F88F2C
wdt:P433
22
wdt:P478
30
p:P356
wds:Q55309836-BDC2903D-5DB9-42B1-A054-29DEC3AD1033
wdtn:P356
n8:JCO.2011.39.4403
wdt:P356
10.1200/JCO.2011.39.4403
p:P932
wds:Q55309836-7D7296A4-EECC-4B46-A1F3-C37BE5E192E9
wdt:P932
5950497